The BLOC1S2 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-engineered polyclonal knockout population, featuring targeted disruption of the BLOC1S2 gene, which encodes an essential subunit of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). This loss-of-function model provides a versatile tool for dissecting BLOC-1?Cdependent trafficking events, with the polyclonal format ensuring representative phenotypic diversity and resilience against off-target clonal effects.
SK-HEP-1 is a human liver adenocarcinoma cell line originally isolated from the ascites of a male patient and is widely employed as a model for hepatic tumorigenesis and endothelial biology. The cell line exhibits characteristics of both epithelial and endothelial lineages, making it particularly useful for investigating the intersection of endosomal trafficking and cancer cell signaling. Its adherent growth and stable karyotype facilitate reproducible experimental workflows, including high-content imaging and drug sensitivity profiling.
BLOC1S2 functions as a core component of the octameric BLOC-1 complex, where it directly interacts with other subunits such as BLOC1S1, DTNBP1 (dysbindin), PLDN (pallidin), and MUTED. The complex serves as a sorting adaptor on early endosomes, coupling molecular motors like KIF13A to cargo destined for melanosomes, platelet dense granules, and other lysosome-related organelles. BLOC1S2 expression is transcriptionally regulated by the MITF transcription factor downstream of PI3K-AKT-mTOR signaling, linking nutrient sensing to organelle biogenesis. Through its role in BLOC-1, BLOC1S2 facilitates the AP-3?Cdependent trafficking of melanosomal proteins such as TYRP1 and TYR, as well as the delivery of lysosomal cathepsins and the recycling of endocytic receptors. Knockout of BLOC1S2 therefore disrupts these coordinated trafficking pathways, which are critical for pigmentation, hemostasis, and lysosomal function.
In the SK-HEP-1 hepatic adenocarcinoma context, disruption of BLOC1S2 is expected to impair lysosome-related organelle formation and endosomal sorting, thereby affecting processes relevant to tumor biology, such as autophagy flux, lysosomal enzyme secretion, and endocytic signaling. Although SK-HEP-1 cells do not produce melanin, they engage BLOC-1?Cdependent pathways for lysosomal maintenance and may exhibit altered sensitivity to lysosomotropic agents like hydroxychloroquine. This knockout model thus permits the study of BLOC1S2??s contributions to liver cancer cell homeostasis and its potential link to disorders such as Hermansky-Pudlak syndrome and lysosomal storage diseases.
Researchers can utilize these polyclonal knockout cells to explore the role of BLOC-1 in endolysosomal trafficking, validate candidate interacting partners, and screen for small molecules that modulate lysosomal function. Representative applications include Western blotting and RT-qPCR for knockout confirmation, immunofluorescence microscopy for lysosomal markers (e.g., LAMP1, LAMP2) and endocytic cargo, flow cytometry for surface receptor recycling, and cathepsin activity measurements. Drug sensitivity assays using hydroxychloroquine can assess the contribution of BLOC1S2 to lysosomal cell death pathways. For further technical information and ordering details, please contact Ascent Research.
